Response to Therapy
After ablation (cavo-tricuspid isthmus or CTI ablation) for AFL, ~60% of patients will exhibit AF over the subsequent 5 years25. Stratifying those patients presenting with AFL who are likely to develop AF has management implications with regards to ongoing arrhythmia surveillance, long-term anticoagulation and index ablation strategy. It has been suggested in some patients who present with AFL alone, a combined AFL/prophylactic AF ablation strategy is warranted26. To date, the clinical utility of polygenic risk scores in AF management has been limited27. Our data suggest a potential use case for an AF GRS in clinical practice. AF polygenic risk appears to identify those patients presenting with AFL where future AF is likely.